

ENDPOINTS NEWS



PROTOCOLS

Genenta adds \$8M for gene

therapy R&D



⇒ Milan-based Genenta Science raised an \$8 million B round for its work in hematopoietic stem cell gene therapy for tumor treatment. The round was led by Italian, British, and Swiss private investors, family offices, and business angels, its Series A investors and Board Members. Genenta, led by CEO Pierluigi Paracchi, has raised more than \$20 million for its work to date. Novartis vet Guido Guidi joined the board and Dana-Farber's Ken Anderson joined the scientific advisory group at the company.